IMMUNOME IMNM 深 沪
等待开盘 09-23 09:30:00 美东时间
9.77
+0.380
+4.05%
华盛通- 最 高10.03
- 今 开9.79
- 成交量 134.63万股
- 最 低 9.36
- 昨 收 9.39
- 总市值 8.50亿
- 52周最高 15.125
- 市盈率 静 --
- 换手率 1.55%
- 52周最低 5.1501
- 委 比 -47.54%
- 总股本 8704.50万
- 历史最高 63.78
- 量 比 0.91
- 振 幅 7.14%
- 历史最低 2.09
- 每 手 1
- 风险率 4.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
今天 09:52
Goldman Sachs Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $26
Goldman Sachs analyst Salveen Richter initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $26.
09-22 19:57
What Analysts Are Saying About Gilead Sciences Stock
Gilead Sciences (NASDAQ:GILD) underwent analysis by 5 analysts in the last quar...
09-16 21:01
Where Immunome Stands With Analysts
Immunome (NASDAQ:IMNM) underwent analysis by 4 analysts in the last quarter, re...
09-06 05:02
Craig-Hallum Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $26
Craig-Hallum analyst Adam Vogel initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $26.
09-05 22:05
Immunome (IMNM) Initiated with a Buy at Craig-Hallum
In a report released today, from Craig-Hallum initiated coverage with a Buy rat...
09-05 21:15
美股大行评级 | 英伟达、Snowflake、万国数据、沃尔玛、Target等均获大行上调目标价
今日重点评级关注：杰富瑞：维持aTyr Pharma"买入"评级，目标价从9美元升至17美元；花旗：维持Ionis制药"买入"评级，目标价从65美元升至69美元
08-25 08:34
Evercore ISI Group Initiates Coverage On Immunome with Outperform Rating, Announces Price Target of $18
Evercore ISI Group analyst Cory Kasimov initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating and announces Price Target of $18.
08-23 00:50
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
JP Morgan Maintains Overweight on Immunome, Lowers Price Target to $22
JP Morgan analyst Brian Cheng maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $23 to $22.
08-08 05:12
